Compare ASMB & KNDI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASMB | KNDI |
|---|---|---|
| Founded | 2005 | 2002 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Auto Manufacturing |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 553.6M | 67.8M |
| IPO Year | 2010 | N/A |
| Metric | ASMB | KNDI |
|---|---|---|
| Price | $30.71 | $0.89 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $43.40 | N/A |
| AVG Volume (30 Days) | 154.5K | ★ 199.4K |
| Earning Date | 11-10-2025 | 03-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $37,191,000.00 | ★ $104,035,613.00 |
| Revenue This Year | $33.33 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 31.30 | N/A |
| 52 Week Low | $7.75 | $0.78 |
| 52 Week High | $39.71 | $1.81 |
| Indicator | ASMB | KNDI |
|---|---|---|
| Relative Strength Index (RSI) | 40.46 | 48.72 |
| Support Level | $30.18 | $0.80 |
| Resistance Level | $33.71 | $0.93 |
| Average True Range (ATR) | 1.92 | 0.06 |
| MACD | -0.28 | 0.01 |
| Stochastic Oscillator | 19.43 | 55.59 |
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.
Kandi Technologies Group Inc is engaged in developing, manufacturing, and commercializing fully electric vehicle products and related technologies. Its products mainly consist of EV parts, EV products, and off-road vehicles, including All-Terrain Vehicles (ATVs), UTVs, go-karts, electric scooters, electric self-balancing scooters, and associated parts, and Lithium-ion cells, etc. The company generates maximum revenue from the sale of Off-road vehicles and associated parts. Geographically, it derives maximum revenue from the United States and other countries, followed by China.